STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
Food and Drug Administration approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the company has said could become its top-selling product ever, STAT says.
- New results from a closely watched clinical trial showed that weight loss drugs are effective for children as young as 6, though some doctors say they are concerned about the prospect of prescribing these medications to such young patients, The New York Times writes.
- The study, presented at the medical conference Obesity Week, examined children ages 6 to 11 who were taking semaglutide, the compound in Ozempic and Wegovy.
- Most children in the trial had severe obesity, meaning they had a body mass index of 35 or higher.
Analysts broadly see giredestrant becoming a multibillion-dollar blockbuster if Roche wins approval in other forms of breast cancer.
It gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its Genentech subsidiary, though in recent years it has fallen behind rivals in oncology.
- The approval for the drug, known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting.
- After 68 weeks, nearly 40% of those who took the drug no longer had obesity, compared with none of the patients on a placebo.
- And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us.
- Continue to STAT+ to read the full story….
- As for the official mascots, they are happily snoozing in their respective corners.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →